AI medical unicorn Hangzhou Diagens Biotechnology Co., Ltd. makes a second attempt to list on the Hong Kong Stock Exchange: backed by the world's first medical imaging large model, with a 30.6% market share ranking first - NewTimeSpace
AI medical unicorn Hangzhou Diagens Biotechnology Co., Ltd. makes a second attempt to list on the Hong Kong Stock Exchange: backed by the world's first medical imaging large model, with a 30.6% market share ranking first

Hangzhou Diagens Biotechnology Co., Ltd. once again submitted an application for listing to the Hong Kong Stock Exchange on January 6. Relying on the world's largest parameter iMedImageTM medical imaging large model, the company firmly ranks as the leader in China's chromosome karyotype analysis market with a 30.6% market share.

NewTimeSpace · 2026-01-07
Hangzhou Diagens Biotechnology Co., Ltd.IPOsubmissionAI medical care
China Universal CSI All Share Investment Banking & Brokerage Index ETF (560090) Up 3.02%, Latest Size Reaches 3.528 Billion Yuan - NewTimeSpace
China Universal CSI All Share Investment Banking & Brokerage Index ETF (560090) Up 3.02%, Latest Size Reaches 3.528 Billion Yuan

As of 10:31 on January 6, 2026, Securities ETF Leader (560090) rose 3.02%, with the latest price at 1.36 yuan.

NewTimeSpace · 2026-01-06
Securities ETF Leader560090.SHETF
Sunmi Technology Receives CSRC Filing for HK IPO and Full Circulation - NewTimeSpace
Sunmi Technology Receives CSRC Filing for HK IPO and Full Circulation

Shanghai Sunmi Technology Group has obtained CSRC filing approval for its proposed Hong Kong IPO of up to 46,000,000 shares and conversion of 261,415,724 domestic shares held by 13 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.

NewTimeSpace · 2026-01-06
Sunmi TechnologyCSRCIPO
Hangzhou DESH Bio Gets Regulatory Approval for Hong Kong Listing and Full Circulation - NewTimeSpace
Hangzhou DESH Bio Gets Regulatory Approval for Hong Kong Listing and Full Circulation

Hangzhou DESH Biological Technology has received CSRC filing approval for its proposed Hong Kong IPO of up to 31,004,000 shares and conversion of 80,880,000 domestic shares held by 27 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.

NewTimeSpace · 2026-01-06
Hangzhou DESH BioIPOFull Circulation
Haizhi Technology Gets CSRC Approval for HK Listing, 40 Shareholders to Convert 372.4M Domestic Shares to H-shares - NewTimeSpace
Haizhi Technology Gets CSRC Approval for HK Listing, 40 Shareholders to Convert 372.4M Domestic Shares to H-shares

Beijing Haizhi Technology Group has received CSRC filing approval for its proposed Hong Kong IPO of up to 47,584,600 shares and conversion of 372,400,480 domestic shares held by 40 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.

NewTimeSpace · 2026-01-06
Haizhi TechnologyApproval for HK ListingIPO
Knowledge Atlas(02513.HK): Launches IPO on December 30, proposing to globally offer 37.4195 million H shares - NewTimeSpace
Knowledge Atlas(02513.HK): Launches IPO on December 30, proposing to globally offer 37.4195 million H shares

Knowledge Atlas(02513.HK) announced that it will conduct an IPO from December 30, 2025 to January 5, 2026, planning to globally offer 37.4195 million H shares, with an offer price of HK$116.20 per share. The H shares are expected to start trading on the Hong Kong Stock Exchange at 9:00 a.m. on January 8, 2026.

NewTimeSpace · 2025-12-30
Knowledge Atlas02513.HKIPOIPO Offering